Treatment With Anakinra, a Recombinant IL-1 Receptor Antagonist, Unlikely to Induce Lasting Remission in Patients With CGD Colitis

[1]  Sarmed S. Sami,et al.  A Randomized Comparative Effectiveness Trial of Novel Endoscopic Techniques and Approaches for Barrett’s Esophagus Screening in the Community , 2015, The American Journal of Gastroenterology.

[2]  R. Xavier,et al.  IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans , 2014, Proceedings of the National Academy of Sciences.

[3]  S. Holland,et al.  Gastrointestinal Histopathology in Chronic Granulomatous Disease: A Study of 87 Patients , 2013, The American journal of surgical pathology.

[4]  R. Fitzgerald,et al.  Randomized crossover study comparing efficacy of transnasal endoscopy with that of standard endoscopy to detect Barrett's esophagus. , 2012, Gastrointestinal endoscopy.

[5]  S. Holland,et al.  Residual NADPH oxidase and survival in chronic granulomatous disease. , 2010, The New England journal of medicine.

[6]  J. Orange,et al.  Complications of tumor necrosis factor-α blockade in chronic granulomatous disease-related colitis. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  S. Holland,et al.  Gastrointestinal involvement in chronic granulomatous disease. , 2004, Pediatrics.

[8]  Richard B. Johnston,et al.  Chronic Granulomatous Disease: Report on a National Registry of 368 Patients , 2000, Medicine.

[9]  R. F. Harvey,et al.  A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY , 1980, The Lancet.